CLL1 car-t cells for relapsed or refractory acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new treatment using your own immune cells, modified to find and kill leukemia cells that have a marker called CLL1. It is for people with AML that has come back or not responded to standard care, and it may be followed by a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML (acute myeloid leukemia) that has returned or not responded to standard treatments.
- Your leukemia cells have a protein called CLL1 on more than half of them.
- A stem cell donor is available for you in case you need a transplant after this therapy.
- You are generally well enough to do daily activities (performance status 0 or 1).
- Your heart, kidneys, liver, and lungs are working well enough to participate.
- You do not have certain other health problems, like active infections, heart disease, or previous cancers, unless they've been cured for at least 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a universal CAR-T cell therapy for acute myeloid leukemia (AML), a type of blood cancer. The treatment uses specially engineered immune cells to target leukemia cells with certain markers, and the trial aims to see if it is safe and effective for patients whose leukemia has not responded to standard treatments.
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
This trial tests a new treatment using your donor's immune cells that are engineered to find and attack cancer cells with a specific marker called CD117. It's for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments.
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
This trial tests an experimental CAR-T cell therapy for acute myeloid leukemia (AML) that has returned or not responded to standard treatments. It uses a special marker on leukemia cells (CLL-1) to target and kill them.
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.